Skip to main content

Table 2 Univariate and multivariable analyses for composite clinical outcome

From: Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort

 

Univariate analysis

Multivariable analysis (stepwise AIC)

Variable

HR (95% CI)

p-value

HR (95% CI)

p-value

Risk factors for HIV acquisition

 MSM vs. heterosexual transmission

0.547 (0.28-1.068)

0.0773

0.379 (0.174-0.828)

0.0149

 IDU vs. heterosexual transmission

2.165 (1.383-3.388)

0.0007

2.608 (1.31-5.19)

0.0063

Log10 HIV RNA (copies/mL)

1.516 (1.264-1.818)

<0.0001

1.612 (1.278-2.034)

<0.0001

LDL cholesterol (mg/dl)

0.995 (0.99-1.001)

0.0819

0.994 (0.989-1)

0.0377

Serum glucose (mg/dl)

1.026 (1.02-1.033)

<0.0001

1.034 (1.026-1.042)

<0.0001

γGT (IU/L)

1.003 (1.002-1.004)

<0.0001

1.004 (1.003-1.005)

<0.0001

eGFR (mL/min/1.73 m2)

0.968 (0.956-0.98)

<0.0001

0.959 (0.947-0.972)

<0.0001

Fib-4

1.033 (1.022-1.043)

<0.0001

1.03 (1.018-1.043)

<0.0001

Log10 NLR

1.31 (1.084-1.582)

0.0052

1.319 (1.047-1.662)

0.0188

Co-infections with hepatitis viruses

 HBsAg unknown vs. HBsAg negative

1.067 (0.612-1.86)

0.82

2.525 (1.055-6.043)

0.0374

 HCV Ab unknown vs. HCV Ab negative

1.495 (0.907-2.466)

0.1148

0.376 (0.164-0.86)

0.0205

Number of switches in the NRTI backbone

1.08 (1.037-1.125)

0.0002

1.085 (1.025-1.15)

0.0051

Number of AIDS events

1.205 (1.089-1.334)

0.0003

1.278 (1.072-1.523)

0.0063

  1. HR hazard ratio, AIC Akaike Information Criterion, HIV human immuno-deficiency virus, AIDS acquired immune deficiency syndrome, MSM men have sex with men, IDU intravenous drug use, HCV Ab hepatitis C virus antibodies, HBsAg Hepatitis B virus surface antigen, Fib-4 fibrosis four score, PI proteases inhibitor, cART combination antiretroviral therapy, γGT γ-glutammil-transpeptidase, eGFR estimated glomerular filtration rate, NRTI Nucleoside/nucleotide reverse transcriptase inhibitors, CI confidence interval, NLR neutrophil/lymphocytes ratio, HR hazard ratio, Fib-4 fibrosis 4 score
  2. For quantitative variables, HR indicates the risk for each unit increase